Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Santen Pharmaceutical Co ( (JP:4536) ) just unveiled an update.
Santen Pharmaceutical Co. has released its financial results for the fiscal year ending March 31, 2025, reporting a slight decrease in revenue by 0.6% but a significant increase in net profit by 34.3%. The company also announced plans for a share repurchase and increased dividends, indicating a strategic focus on enhancing shareholder value despite the anticipated revenue decline in the coming year.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen1900.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily operating in the pharmaceutical industry. The company focuses on developing and marketing products related to eye care, positioning itself as a leader in ophthalmology.
Average Trading Volume: 1,229,031
Technical Sentiment Signal: Hold
Current Market Cap: Yen499.5B
For a thorough assessment of 4536 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue